NEPT
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
The CIN framework assigns Neptune Wellness Solutions a Underweight rating at 29/100, with conviction of 1 out of 5. The composite is a fixed blend of four pillars — fundamentals at 35 percent, regulatory at 25, market at 25, and editorial at 15 — and each contribution is inspectable. The strongest contribution comes from the regulatory pillar at 49, and pulls the composite toward the lower edge of the band. Fundamentals lags at 6, softening what would otherwise be a stronger reading.
Under the hood, the data points sit as follows: reported revenue growth of -37.8 percent year over year, an operating margin of -232.9 percent. Each of those figures ties back to a specific input in the pillar breakdown. Every input flowing into the pillar table comes from primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, filtered through CIN newsroom density. The 336-ticker CIN universe is scored deterministically, so Neptune Wellness Solutions can be compared against the US operator peer set on identical inputs, refreshed on the ingest cycle.
The rating turns on regulatory pace. Filings landing at above the trailing-90-day cadence, combined with an unblemished enforcement record, would carry Neptune Wellness Solutions above the Underweight anchor; a lull would soften the read.
- IR / PR agency
- KCSA Strategic Communications
- IR email
- investors@neptunecorp.com
- IR page
- Investor relations
- Phone
- 1-877-426-7829
- CEO
- Michael de Geus (Interim)
- CFO
- Lisa Gainsborg (Interim)
- SEC CIK
- 0001401395
- Website
- Company website
- Market cap
- $0.9M
- Enterprise value
- $6.1M
- Price to book
- 0.56
- Price to sales
- 0.02
- EV / EBITDA
- -0.48
- Revenue (TTM)
- $39.1M
- Gross profit (TTM)
- $-8.5M
- EBITDA
- $-45.2M
- Operating margin
- -232.9%
- Profit margin
- -136.8%
- Rev growth YoY
- -37.8%
- Return on equity
- -818.5%
- Return on assets
- -67.0%
- EPS (TTM)
- $-200.20
- Wall St. target price
- $26.25
- Shares outstanding
- 4.5M
- Insider ownership
- 43.8%
- Institutional ownership
- 6.1%
- Beta
- 2.19
- Full-time employees
- 50
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for NEPT (NEPT)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for NEPT (NEPT), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for NEPT are maintained by Cannabis Investor News and refreshed throughout the trading day.